³Ø²ñȯɽ
¸¦µæ¶ÈÀÓ













¥µ¥¤¥È¥Þ¥Ã¥×

¢£¿À¸ÍÄ«Æüɱ¡
--¿À¸Í»ÔÂèÆó¼¡µßµÞɱ¡--
¢©653-0801
¿À¸Í»ÔĹÅĶè˼²¦»ûÄ®3-5-25
Ï¢ÍíÀè
ÅÅÏá§ 078-612-5151¡ÊÂå¡Ë
£Æ£Á£Ø¡§078-612-5152
email¡§info@kobe-asahi-hp.com


¡¡
HOME¤ØÌá¤ë

¡¡

¢§³Ø²ñ³èư £²£°£°£¶Ç¯°Ê¹ß¡Ê2005ǯ°ÊÁ°¤Î¤â¤Î¤Ï¤³¤Á¤é¡Ë
³«ºÅǯ·î ³Ø²ñ̾ ±é¼Ô ±éÂê̾
2006ǯ1·î Âè21²óÆüËÜÀÅÌ®·ÐIJ±ÉÍܳزñ °ÂÆ£·ò¼£ NST²ðÆþ¤Ë¤è¤ë±ÉÍÜÊäµë·ÁÂÖ¤ÎÊѲ½
2006ǯ2·î Âè84²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ »°ÅÄ·ÉÆó RFA¼£ÎŤˤª¤±¤ë³°²ÊŪ´ØÍ¿¤ÎÍ­¸úÀ­
2006ǯ3·î Âè76²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñÃÏÊý²ñ °ÂÆ£·ò¼£ Ç´±Õ»ºÀ¸ÃÀ´É¼ðáç¤Î°ìÎã
2006ǯ5·î Âè92²óÆüËܾò½´ïɳزñÁí²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ë¤ß¤é¤ì¤¿´ÎÆâ¿ȯ¾®·ëÀá¤Î°ìÎã
2006ǯ5·î Âè42²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤Î¼£ÎŸú²Ìͽ¬¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹dynamics¤Î¸¡Æ¤
2006ǯ5·î Âè42²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍѼ£ÎŤθú²Ìͽ¬¤Ë¤ª¤±¤ë2¡Ç-5¡Ç¥ª¥ê¥´¥¢¥Ç¥Ë¥ì¥¤¥È¹çÀ®¹ÚÁÇ¡Ê2-5AS¡Ë¤Î±þÅúÀ­¤Î¸¡Æ¤
2006ǯ7·î Âè42²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ë¤ß¤é¤ì¤¿´ÎÆâ¿ȯ¾®·ëÀá¤Î°ì¾ÉÎã
2006ǯ7·î Âè42²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ CTA½ê¸«¤¬Ë³·ìÀ­¤òÊݤ俤ޤޡ¢CTAP½ê¸«¤¬Ç»À÷¤«¤é6¥ö·î¤Î·Ð²á¤Çperfusion defect¤ËÊѲ½¤·¤¿¹âʬ²½´â¤Î¾ÉÎã
2006ǯ7·î Âè42²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ËýÀ­´Î¼À´µ¤òÇØ·Ê¤È¤¹¤ë2cm°Ê²¼·ëÀá¤ÎCTA¡¦CTAP½ê¸«¤ÈÉÂÍý½ê¸«¤ÎÂÐÈæ
2006ǯ9·î Âè85²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÉØÌÚ½¨°ì Åö±¡¤Ë¤Æ·Ð¸³¤·¤¿È󥦥¤¥ë¥¹À­µÞÀ­½Å¾É´Î¾ã³²¤Î3¾ÉÎã
2006ǯ10·î DDW¡¡Japan¡¡2006 ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍѼ£ÎŤθú²Ìͽ¬¤Ë¤ª¤±¤ë2¡Ç-5¡Ç¥ª¥ê¥´¥¢¥Ç¥Ë¥ì¥¤¥È¹çÀ®¹ÚÁÇ¡Ê2-5AS¡Ë¤Î±þÅúÀ­¤Î¸¡Æ¤
2006ǯ10·î DDW¡¡Japan¡¡2006 ¶â¼éÎÉ CTA½ê¸«¤¬Ë³·ìÀ­¤òÊݤ俤ޤޡ¢CTAP½ê¸«¤¬Ç»À÷¤«¤é6¥ö·î¤Î·Ð²á¤Çperfusion defect¤ËÊѲ½¤·¤¿¹âʬ²½´â¤Î¾ÉÎã
2006ǯ10·î DDW¡¡Japan¡¡2006 ¶â·¼Æó C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPeg-IFN¦Á2b¡¦¥ê¥Ð¥Ó¥ê¥óÎÅË¡¤Ë¤ª¤±¤ë¥Ý¥é¥×¥ì¥¸¥ó¥¯Ê»ÍѤˤè¤ë·ìµå¸º¾¯¤ª¤è¤Ó´Îµ¡Ç½¤ËÍ¿¤¨¤ë±Æ¶Á¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤
2006ǯ10·î DDW¡¡Japan¡¡2006 °æËÜÊÙ AMA±¢À­¤Î¤â¤ÈPBC¤È´Î¼Â¼Á¤ËµÞÀ­´Î±êÍͽ긫¤ÈÃÀ½Á¤¦¤ÃÞü¤òǧ¤á¤¿AIH¤Î½ÅÊ£¾É¸õ·²¤Î°ì¾ÉÎã-ÆÃ¤ËÎ×¾²ÉÂÍý³ØÅª¸¡Æ¤
2006ǯ10·î DDW¡¡Japan¡¡2006 »°ÅÄ·ÉÆó ½Ð·ì¸»¤¬ç£Æ°Ì®¤ÇÆâ»ë¶ÀŪ»ß·ì¤¬º¤Æñ¤Ç¤¢¤Ã¤¿½Ð·ìÀ­°ßÄÙáç¤Î°ìÎã
2007ǯ2·î Âè86²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÎëÌÚÆØ ÌôºÞÀ­´Î¾ã³²¤ÎÆÃħŪÁÈ¿¥½ê¸«¤òÄ褷¤¿°ìÎã
2007ǯ2·î Âè86²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÃöÀî¹°»Ì È󥢥륳¡¼¥ëÀ­»éËÃÀ­´Î±ê¡ÊNASH¡Ë¤Èñ½ã»éËôΤδÕÊ̤λî¤ß
2007ǯ3·î APASL ¶â¼éÎÉ Blood cell and liver function changes by PEG-IFN-¦Á2b plus RBV with zinc
2007ǯ3·î APASL ¶â¼éÎÉ 2'-5'-oligoadenylated synthetase response ration predicting effect of PEG-IFN ¦Á2b plus Ribavirin
2007ǯ4·î Âè93²óÆüËܾò½´ïɳزñÁí²ñ ¶â¼éÎÉ ¹âÎð¼ÔC·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN/Ribavirin¡ÊÊ»ÍÑÎÅË¡¡Ë¤Î¸¡Æ¤
2007ǯ4·î Âè93²óÆüËܾò½´ïɳزñÁí²ñ ÃöÀî¹°»Ì PIVKA­¶°Û¾ï¹âÃͤòÄ褷¡¢Â¤±ÆCT¤Ë¤ÆÂ¿È¯¤¹¤ë¹­ÈϤÊlow¡¡density¡¡area¤òǧ¤á¤¿¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤΰìÎã
2007ǯ5·î Âè43²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ 2£ã£í°Ê²¼¤Î·ëÀá¤ËÂФ¹¤ë¼è°·¤¤¤Ë¤Ä¤¤¤Æ¤ÎÄó¸À-·ì´É¤±Æ²¼CT¡¢À¸¸¡½ê¸«¤òƧ¤Þ¤¨¤Æ-
2007ǯ5·î Âè43²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤Î¼£ÎŸú²Ì¤Ë´ØÏ¢¤¹¤ë½É¼ç¦°ø»Ò¤Î¸¡Æ¤-adipocytokine¡¢¥¤¥ó¥¹¥ê¥óÄñ¹³À­¡¢´ÎÀþ°Ý²½¡¢ÈîËþ¤òÃæ¿´¤Ë
2007ǯ5·î Âè43²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤Î¼£ÎŸú²Ìͽ¬¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹dynamics¤Î¸¡Æ¤
2007ǯ5·î Âè43²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤Î¼£ÎŸú²Ìͽ¬¤Ë¤ª¤±¤ë2'-5'¥ª¥ê¥´¥¢¥Ç¥Ë¥ì¥¤¥È¹çÀ®¹ÚÁǤαþÅúÀ­¤Î¸¡Æ¤
2007ǯ5·î Âè43²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ ËýÀ­C·¿´Î±ê¤Ë¤ª¤±¤ëËö¾¿·ìÃæ¤ÎIgG¹³·ì¾®ÈÄ´ØÏ¢ÆÃ°Û¼«¸Ê¹³ÂλºÀ¸BºÙ˦¤Î¸¡½Ð¤ª¤è¤Ó¤«¤«¤ëBºÙ˦½Ð¸½ÉÑÅÙ¤ÎIFN¼£ÎÅÁ°¸å¤Ë¤ª¤±¤ëÊÑÆ°-A¡¡pilot¡¡study
2007ǯ6·î Âè43²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ CTA¤¬Ç»À÷¡¢CTAP¤âÇ»À÷¤·¤¿¹âʬ²½´ÎºÙ˦´â¤Î°ì¾ÉÎã
2007ǯ6·î Âè43²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ë´Î¹ÅÊѤˤߤé¤ì¤¿Â¿È¯À­Â¿·ìÀ­·ëÀá¤Î2¾ÉÎã
2007ǯ6·î Âè43²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ 2cm°Ê²¼¤Î·ëÀá¤ËÂФ¹¤ë¼è°·¤¤¤Ë¤Ä¤¤¤Æ¤ÎÄó¸À-·ì´É¤±Æ²¼CT¡¢À¸¸¡½ê¸«¤òƧ¤Þ¤¨¤Æ-
2007ǯ9·î SISL¡¡Seoul International Liver Symposium ¶â¼éÎÉ Prediction of efficient virological response to PEG-IFN/RBV combination therapy by NS5A sequences of HCV in pre-treatment sera
2007ǯ9·î Âè87²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÉØÌÚ½¨°ì AIH,PBC¡¡¥ª¡¼¥Ð¡¼¥é¥Ã¥×¾É¸õ·²¤Î°ìÎã
2007ǯ9·î Âè183²óÆüËÜÆâ²Ê³Ø²ñ¶áµ¦ÃÏÊý²ñ ÅÄÃæÂçÊå ÃøÌÀ¤Ê·ì°µÊÑÆ°¤òǧ¤á¡¢Á޴ɲ¼¿Í¹©¸ÆµÛ´ï´ÉÍý¸å¤Ë¿ÇÃǤ¬¤Ä¤¤¤¿¥®¥é¥óŽ¥¥Ð¥ì¡¼¾É¸õ·²¤Î°ìÎã
2007ǯ10·î JDDW2007¡¡Âè11²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¦Á2b¡ÜRibavirin¡ÊÊ»ÍÑÎÅË¡¡Ë¤Ë¤ª¤±¤ë¥¤¥ó¥¹¥ê¥óÄñ¹³À­¤È¼£ÎŸú²Ì¡¢´ÎÁÈ¿¥½ê¸«¡¢BMI¤È¤Î´ØÏ¢
2007ǯ10·î JDDW2007¡¡Âè11²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¦Á2b¡ÜRibavirin¡ÊÊ»ÍÑÎÅË¡¡Ë¤Î¼£ÎŸú²Ì¤È¥«¥¹¥Ñ¡¼¥¼3³èÀ­¤È¤Î´Ø·¸
2007ǯ10·î JDDW2007¡¡Âè11²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¡¢Ribavirin¡ÊÊ»ÍÑÎÅË¡¡Ë¤Î¸ú²Ì¤È·ìÀ¶»é¼Á¥Þ¡¼¥«¡¼¤È¤Î´Ø·¸
2007ǯ12·î Âè37²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ PEG-IFN¡¢Ribavirin¤ÎÊ»ÍÑÎÅË¡½ªÎ»¸å¡¢10Æü¸å¤Ëµ¤´É»ÙÇÙ±ê¤ò¹çÊ»¤·¹³À¸ºÞ¤òÅêÍ¿¤·¤¿¤¬¡¢¤½¤Î10Æü¸å¤Ë´Ö¼ÁÀ­ÇÙ±ê¤òȯ¾É¤·¤¿°ì¾ÉÎã
2007ǯ12·î Âè37²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ 2ǯȾ¤Î·Ð²á¤Ç¡¢Ã±½ãÀ­»éËôΤ«¤éF2 stage¤ÎNASH¤Ë¿Ê¹Ô¤·¤¿1¾ÉÎã
2007ǯ12·î

Âè37²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ

¶â¼éÎÉ °ìÈÌɱ¡¤Ë¤ª¤±¤ëÀ¸Âδΰܿ¢¼£ÎŤΥÁ¡¼¥à°åÎÅ
2007ǯ12·î Âè37²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ HLA DR4,DR8¤¬¸¡½Ð¤µ¤ì¤¿¤¬¡¢WBË¡¤Ç¤â¹³M2¹³ÂΤϱ¢À­¤Ç¡¢¥¹¥Æ¥í¥¤¥É¤¬ÁÕ¸ù¤·¤¿AIH-PBC¡ÊAIC¡Ë½ÅÊ£¾É¸õ·²¤Î1Îã
2008ǯ2·î Âè88²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ

°ÂÆ£·ò¼£

PEG¡¡IFN¡Ü¥ê¥Ð¥Ó¥ê¥ó¼£ÎŸåµÚ¤Ó¼£ÎÅÃæ¤ËµÞÀ­ç¹±ê¤òȯ¾É¤·¤¿C·¿ËýÀ­´Î±ê¤Î£²Îã
2008ǯ2·î Âè88²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ Ëܲ¬Ëãͳ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ëacute on chronic¤Ë·à¾É´Î±ê¤òȯ¾É¤·¤¿¤¬¡¢ÊÝ¸Ū¼£ÎŤǵßÌ¿¤·ÆÀ¤¿£±Îã
2008ǯ2·î Âè88²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÅÄÃæÂçÊå Àü¹¦À­Ê¢Ëì±ê¤ò·Àµ¡¤Ëȯ¸«¤µ¤ì¤¿¾®Ä²·¿¥¯¥í¡¼¥óÉ¤Σ±Îã
2008ǯ4·î Âè43²óEASL ¶â¼éÎÉ Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2cm
2008ǯ5·î Âè44²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤˤª¤±¤ë¿·ìÀ­Â¿·ëÀáÀ­·ëÀá
2008ǯ5·î Âè44²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ Ë³·ìÀ­Å¾°ÜÀ­´Î¥«¥ë¥Á¥Î¥¤¥É¤Î1¾ÉÎã
2008ǯ5·î Âè44²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ B·¿´Î¹ÅÊѤòÇØ·Ê¤Ë¤â¤Ä¹Å²½·¿HCC¤Î£±¾ÉÎã
2008ǯ5·î Âè44²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ RFA¤Ç¤Ï¤Ê¤¯PEIT¼£ÎŤòÁªÂò¤·¤¿15mm°Ê²¼¹âʬ²½·¿´ÎºÙ˦´â¤Î3¾ÉÎã
2008ǯ6·î Âè44²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ È󥢥륳¡¼¥ëÀ­»éËÃÀ­´Î±ê´µ¼Ô¡ÊNASH¡Ë¤Ë¤ª¤±¤ë´Î»éËò½¡¢´ÎÀþ°Ý²½¤Ë±Æ¶Á¤ò¤ª¤è¤Ü¤¹°ø»Ò¤Î¸¡Æ¤¡½adipocytokines¤òÃæ¿´¤Ë¡½
2008ǯ6·î Âè44²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ PEG¡¡IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤Î¼£ÎŸú²Ìͽ¬¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹dynamics¤Î¸¡Æ¤
2008ǯ6·î Âè44²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ ËýÀ­C·¿´Î±ê¤Ë¤ª¤±¤ëËö¾¿·ìÃæ¤ÎIgG·¿¹³·ì¾®ÈÄÆÃ¼«¸Ê¹³ÂλºÀ¸BºÙ˦¤Î¸¡½ÐµÚ¤Ó¤«¤«¤ëBºÙ˦¿ô¤ÈËö¾¿·ì·ì¾®ÈÄ¿ô¤È¤Î´ØÏ¢À­¤Ë¤Ä¤¤¤Æ
2008ǯ9·î Âè89²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ À¾ÀîÎË Trousseau¾É¸õ·²¤È¿ÇÃǤµ¤ì¤¿ç¹´â´Î¿ȯž°Ü¤Î°ìÎã
2008ǯ9·î Âè89²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ¹ýͺ°ìϯ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤηвáÃæ¤ËÆÃȯÀ­Ê¢¹ÐÆâ½Ð·ì¤òÄ褷¤¿2Îã
2008ǯ10·î JDDW2008Âè12²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ ºßÆüÆüËܿ͡¢ºßÆü¥³¥ê¥¢¥ó¡¢ºßÃæ¹ñÃæ¹ñ¿Í¡¢ºßÃæ¹ñ¥³¥ê¥¢¥ó¤Ë¤ª¤±¤ëE·¿´Î±ê¥¦¥¤¥ë¥¹´¶À÷Ψ¤Ë´Ø¤¹¤ë±Ö³ØÅª¸¦µæ
2008ǯ10·î JDDW2008Âè12²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ 1b·¿¹â¥¦¥¤¥ë¥¹Î̹âÎð¼ÔC·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG IFN¦Á-2b/¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¡ÊÊ»ÍÑÎÅË¡¡Ë¤Î¸¡Æ¤-ȯ´âÍÞÀ©¤ÈÃæÃÇÂкö¤òÃæ¿´¤Ë-

2008ǯ11·î

Âè187²óÆüËÜÆâ²Ê³Ø²ñ¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ ÈéÉæ¶Ú±ê¤òÇØ·Ê¤ËÊ¢ÉôËÄËþ¤ÇÍ象¤·¡¢µÞ®¤Ë»à¤Ë»ê¤Ã¤¿1˶¸¡Îã
2008ǯ12·î Âè37²óÆüËܴΡ³Ø²ñÅìÉô²ñ ¶â¼éÎÉ ¥Ú¥°¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¡ÊÊ»ÍÑÎÅË¡¡Ë¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹Â¦SVR¡¢Non-SVRͽ¬°ø»Ò¤Î¸¡Æ¤µÚ¤ÓÁá´ü¥¦¥¤¥ë¥¹¥À¥¤¥Ê¥ß¥Ã¥¯¥¹¤È¤Î´Ø·¸
2008ǯ12·î Âè37²óÆüËܴΡ³Ø²ñÅìÉô²ñ ¶â¼éÎÉ ¥Ú¥°¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¡ÊÊ»ÍÑÎÅË¡¡Ë¤ÇµÞÀ­ç¹±ê¤ò¹çÊ»¤·¡¢16½µ¤ÇÃæÃǤ·¤¿¤¬¡¢Ãø¸ú¤È¤Ê¤Ã¤¿­µb·¿¹â¥¦¥¤¥ë¥¹ÎÌC·¿ËýÀ­´Î±ê¤Î°ì¾ÉÎã
2009ǯ2·î Âè90²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ¹ýͺ°ìϯ µÞ®¤ËÁýÂ礷¤¿Êɳ°È¯°é·¿ÂçIJ´â¤Î£±Îã
2009ǯ2·î Âè90²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ À¾ÀîÎË EOB¤±ÆMRI¤¬¿ÇÃǤËÍ­ÍѤǤ¢¤Ã¤¿8mmÂç¹âʬ²½HCC¾ÉÎã
2009ǯ4·î Âè44²ó¡¡EASL ¶â¼éÎÉ Epidemiology of hepatitis in Northeastern Asia
2009ǯ6·î Âè45²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ 2cm°Ê²¼´Î´â¿ÇÃǤߤª¤±¤ëGD-EOB-DTPA¤±ÆMRI¡ÊEOB-MRI¡Ë¤ÎÍ­ÍÑÀ­
2009ǯ6·î Âè45²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ ´Ú¹ñºß½»´Ú¹ñ¿Í¤Ë¤ª¤±¤ëE·¿´Î±ê¥¦¥¤¥ë¥¹´¶À÷Ψ¤Ë´Ø¤¹¤ë±Ö³ØÅª¸¦µæ-ºßÆüÆüËܿ͡¢¥³¥ê¥¢¥ó¡¢ºßÃæ¹ñÃæ¹ñ¿Í¡¢¥³¥ê¥¢¥ó¤È¤ÎÈæ³Ó
2009ǯ6·î Âè45²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ ËýÀ­C·¿´Î±ê¤Ë¤ª¤±¤ëËö¾¿·ì·ì¾®ÈÄ¿ô¸º¾¯¤Î¥á¥«¥Ë¥º¥à¤Ë¤Ä¤¤¤Æ-Ìȱַì±Õ³ØÅª¸¡º÷¤òÃæ¿´¤Ë-
2009ǯ6·î Âè45²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ ºÙÃÀ´ÉºÙ˦´â¡ÊCoCC¡Ë¤Î2¾ÉÎã-Î×¾²ÉÂÍý³ØÅª¸¦µæ¤Î¸¡Æ¤-
2009ǯ6·î Âè3²ó¹ñºÝ´Î´â¥·¥ó¥Ý¥¸¥¦¥à ¶â¼éÎÉ Comparison of diagnostic ability of CECT, Sonazoid CEUS, Gd-EOB-DTPA MRI, and CT arterioportal angiography in diagnosing HCC in nodules smaller than 2cm
2009ǯ7·î Âè45²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ 2cm°Ê²¼Áá´ü´ÎºÙ˦´â¿ÇÃǤˤª¤±¤ë¤±ÆCT¡¢Â¤±ÆUS¡¢Gd-EOB-DTPA¡¡MRI¡ÊEOB¤±ÆMRI¡Ë¡¢Angio£Ã£Ô¤Î¿ÇÃÇǽ¤Î¸¡Æ¤
2009ǯ7·î Âè45²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ £Ã·¿´Î±ê¤òÇØ·Ê¤Ë7cmÂç´Î´âÀÚ½ü¸å18ǯ´ÖĹ´üÀ¸Â¸¤Î1¾ÉÎã
2009ǯ7·î Âè45²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ Ë³·ìÀ­Å¾°ÜÀ­´Î¥«¥ë¥Á¥Î¥¤¥É¤Î1¾ÉÎã
2009ǯ7·î Âè45²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ HCC¼£Î꤯ñÉô°Ì¤ËÂФ¹¤ë¥¬¥¤¥É¥ï¥¤¥ä¡¼¤Ë¤è¤ëRFA¼£ÎÅ
2009ǯ7·î Âè45²óÆüËܴδ⸦µæ²ñ °æËÜ¡¡ÊÙ ÌäÂê¾ÉÎ㸡Ƥ²ñ
2009ǯ9·î Âè91²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ Íû±Ñ¹À PBCÍͤÎÉÂÍý½ê¸«¤òÄ褷¤¿µÞÀ­ÌôʪÀ­´Î¾ã³²¤Î°ìÎã
2009ǯ9·î Âè91²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÃæÅç·½°ì A-P shunt¤È¤·¤Æ4ǯ´Ö·Ð²á´Ñ»¡¤·¤Æ¤¤¤¿¤¬¡¢PIVKA-­¶¤Î¾å¾º¤ò·Àµ¡¤È¤·¤Æ³Îǧ¤µ¤ì¤¿B·¿´ÎºÙ˦´â¤Î°ìÎã
2009ǯ10·î JDDW2009Âè13²óÆüËܴΡ³Ø²ñÂç²ñ ¿½ÌÀɱ Epidemiology of hepatitis E in Northeastern China,South Korea, and Japan.¡Ê´ÎÆÃ´ë1-7¡Ë
2009ǯ10·î JDDW2009Âè13²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ ¥»¥í¥¿¥¤¥×2·¿C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëIFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤ÎÇØ·Ê°ø»ÒµÚ¤ÓÁá´ü¥¦¥¤¥ë¥¹dynamics¤Î¸¡Æ¤
2009ǯ10·î JDDW2009Âè13²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ 1b·¿¹â¥¦¥¤¥ë¥¹C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¡Ü¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅˡ̵¸úÎã¤ËÂФ¹¤ëÆó½Åßɲá·ìÞù¸ò´¹ÎÅË¡¤Î»î¤ß-¥¦¥¤¥ë¥¹dynamics¤òÃæ¿´¤Ë-
2009ǯ10·î JDDW2009Âè13²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ 2£ã£í°Ê²¼Áá´ü´ÎºÙ˦´â¿ÇÃǤˤª¤±¤ë¤±ÆCT¡¢Â¤±ÆUS¡¢EOB¤±ÆMRI¤Î¿ÇÃÇǽ¤Î¸¡Æ¤-Angio¡¡CT¤È¤ÎÈæ³Ó-
2009ǯ10·î JDDW2009Âè13²óÆüËܴΡ³Ø²ñÂç²ñ ë¸ýÈþ¹¬ ´Î¼À´µ¤ÎÉ¿ÇÏ¢·È-¿ÇΞðÊóÄó¶¡½ñ¤«¤é¸«¤¿Ê¼¸Ë¸©´Î¼À´µÀìÌç°åÎŵ¡´Ø¤ÎÌò³ä-¡Ê´ÎŽÜްޏ޼ޮޝŽÌŽß7¡Ë
2009ǯ12·î Âè38²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ ¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÅêÍ¿Ãæ¡¢¼«¸ÊÌȱÖÀ­·ì¾®ÈÄ»çÈÃÉ¡ÊAITP¡Ë¤òȯ¾É¤·¤¿C·¿ËýÀ­´Î±ê¤Î1¾ÉÎã
2009ǯ12·î Âè38²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ C·¿´ØÏ¢´Î¹ÅÊѤòÇØ·Ê¤Ëslow growing ¹âʬ²½HCC¤È¡¢Â¿¿ô¤Î¹¥Ãæµå¿»½á¤òȼ¤¤CD56ÍÛÀ­ºÙ˦¤¬»¶¸«¤µ¤ì¤¿rapid growing HCC¤¬¡¢°Û½êÀ­¤ËȯÀ¸¤·¤¿1Îã
2010ǯ2·î Âè25²óÆüËÜÀÅÌ®·ÐIJ±ÉÍܳزñ °ÂÆ£·ò¼£ ·ìÀ¶°¡±ô¤Î±ÉÍÜ¡¢êóáìɾ²Á¤Ë¤ª¤±¤ëÍ­ÍÑÀ­¤Ë¤Ä¤¤¤Æ
2010ǯ2·î Âè92²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ Íû±Ñ¹À EOB¤±ÆMRI¤¬¿ÇÃǤËÍ­ÍѤǤ¢¤Ã¤¿1cm°Ê²¼¤Î¹âʬ²½´ÎºÙ˦´â¤Î2¾ÉÎã
2010ǯ2·î Âè92²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÃæÅç·½°ì ²¼Éô¾Ã²½´ÉÆâ»ë¶À¸¡ºº¸å¡¢¤¿¤³¤Ä¤Ü·¿¿´¶Ú¾É¤Ë¤è¤ê¿´¸¶À­¥·¥ç¥Ã¥¯¤Ë»ê¤Ã¤¿¤¬¡¢½¸ÃæÅª¿´ÇÙÁÉÀ¸¤Ë¤è¤êµßÌ¿¤·¤¨¤¿°ì¾ÉÎã
2010ǯ4·î Âè45²ó²¤½£´Î¡³Ø²ñ¡ÊEASL¡Ë ¶â¼éÎÉ Comparison of diagnostic capability of contrast-enhanced CT, Sonazoid contrast-enhanced US, Gd-EOB-DTPA MRI and CT arterioportal angiography in detecting histologically proven HCC nodules smaller than 2cm¡¡
2010ǯ5·î Âè46²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ 1b·¿¹â¥¦¥¤¥ë¥¹C·¿ËýÀ­´Î±ê¤ÎPEG-IFN+¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅˡ̵¸úÎã¤ËÂФ¹¤ëÆó½Åßɲá·ìÞù¸ò´¹ÎÅË¡¡ÜIFN-¦Â 4½µ´ÖϢ³ÅêÍ¿¤Î»î¤ß
2010ǯ5·î Âè46²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ 2cm°Ê²¼´ÎºÙ˦´â¿ÇÃǤˤª¤±¤ë¤±ÆCT¡¤Â¤±ÆUS¡¤Angio CT ¤Î¿ÇÃÇǽ¤Î¸¡Æ¤¡ÝEOB¤±ÆMRI¤È¤ÎÈæ³Ó¡Ý
2010ǯ5·î Âè46²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ C·¿´Î¹ÅÊѾÉÎã¤ËÂФ¹¤ëPSE»Ü¹Ô¸å¤ÎËö¾¿·ì·ì¾®ÈÄ¿ôÁý²ÃÎãµÚ¤ÓÉÔ±þÎã¤Ë¤Ä¤¤¤Æ¤ÎÌȱַì±Õ³ØÅª¸¡Æ¤
2010ǯ5·î Âè46²óÆüËܴΡ³Ø²ñÁí²ñ ËÙÅÄ¡¡Çî
El-Shamy
¶â¼éÎÉ
ËýÀ­C·¿´Î±ê¤ËÂФ¹¤ëPEG-IFN¡¿RBV¼£ÎŸú²Ì¤ËµÚ¤Ü¤¹¥¦¥¤¥ë¥¹Â¦°ø»Ò¤Î¤µ¤é¤Ê¤ë¸¡Æ¤¡§¡¡HCV-2aµÚ¤ÓHCV-2b¤ÎNS5A¿ÍÍÀ­¤Ï¼£ÎŸú²Ì¤ÈÁê´Ø¤¹¤ë
2010ǯ6·î ¹ñºÝ¹âÎï³Ø²ñÆüËÜ»ÙÉôÂè14²ó³Ø½ÑÂç²ñ ¶â¼éÎÉ Epidemiology of hepatitis E in Northeastern China,South Korea, and Japan.
2010ǯ7·î Âè46²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ 2cm°Ê²¼ºÙ¾®´ÎºÙ˦´â¿ÇÃǤˤª¤±¤ë¤±ÆCT¡¤Â¤±ÆUS¡¤EOB¤±ÆMRI¤Î¿ÇÃÇǽ¤Î¸¡Æ¤¡ÝAngio CT¤È¤ÎÈæ³Ó¡Ý
2010ǯ7·î Âè46²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ²èÁü¾åCCC¤È´ÕÊ̺¤Æñ¤Ç¤¢¤Ã¤¿Clear cell HCC¤Î¾ÉÎã
2010ǯ7·î Âè46²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ A-P shunt¤È¤·¤Æ4ǯ´Ö·Ð²á´Ñ»¡¤·¤Æ¤¤¤¿¤¬¡¢PIVKA-­¶¤Î¾å¾º¤ò·Àµ¡¤È¤·¤Æ³Îǧ¤µ¤ì¤¿B·¿´ÎºÙ˦´â¤Î°ìÎã
2010ǯ7·î Âè46²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ÌäÂê¾ÉÎ㸡Ƥ²ñ¡ÊCoCC¡Ë
2010ǯ7·î Âè46²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ÌäÂê¾ÉÎ㸡Ƥ²ñ¡Ê»ÒµÜ´â¡Ë
2010ǯ9·î Âè192²óÆüËÜÆâ²Ê³Ø²ñ¶áµ¦ÃÏÊý²ñ °ÂÆ£·ò¼£ C·¿´Î±ê¤òÇØ·Ê¤Ë7cmÂç´Î´âÀÚ½ü¸å20ǯ´ÖĹ´üÀ¸Â¸¤Î1¾ÉÎã
2010ǯ9·î Âè93²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ¶â¼éÎÉ ¿ÇÃǺ¤Æñ¤Ê磸¶È¯¼ðáç¤Î°ìÎã
2010ǯ10·î Âè14²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ 2cm°Ê²¼ºÙ¾®´Î´â¿ÇÃǤˤª¤±¤ë¤±ÆCT¡¢Â¤±ÆUS¡¢EOB¤±ÆMRI¡¢Angio CT¤Î¿ÇÃÇǽ¤Î¸¡Æ¤
2010ǯ10·î Âè14²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ C·¿´Î¹ÅÊÑ¡¢¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ë´ÎºÙ˦´â¡¢´ÎÆâÃÀ´ÉºÙ˦´â¡¢ºÙÃÀ´ÉºÙ˦´â¤¬Â¿Ãæ¿´À­¤ËȯÀ¸¤·¤¿2¾ÉÎ㡽CoCC¤ÎÌȱÖÁÈ¿¥³ØÅª¸¡Æ¤¤ò´Þ¤ó¤Ç¡½
2010ǯ10·î Âè14²óÆüËܴΡ³Ø²ñÂç²ñ °æËÜÊÙ C·¿ËýÀ­´Î±ê1b·¿¹â¥¦¥¤¥ë¥¹ÎÌÊ»ÍÑÎÅˡ̵¸ú´µ¼Ô¤ËÂФ¹¤ëÆó½Åßɲá·ìÞù¸ò´¹ÎÅË¡¡ÊDFPP¡Ë+IFN¦Â2¡Á4½µÏ¢Â³ÅêÍ¿¸åPEG-IFN¦Á-2a+RBVÊ»ÍÑÎÅË¡¤ÎÁá´ü¥¦¥¤¥ë¥¹¥À¥¤¥Ê¥ß¥Ã¥¯¥¹¤Ë¤è¤ëEVRͽ¬
2010ǯ10·î Âè14²óÆüËܴΡ³Ø²ñÂç²ñ °æËÜÊÙ 1b·¿¹â¥¦¥¤¥ë¥¹ÎÌC·¿ËýÀ­´Î±ê¤ÎPEG-IFN+RBVÊ»ÍÑÎÅˡ̵¸úÎã¤ËÂФ¹¤ëÆó½Åßɲá·ìÞù¸ò´¹ÎÅË¡¡ÊDFPP¡Ë+IFN¦Â4½µ´ÖϢ³ÅêÍ¿¸åPEG-IFN¦Á-2a+RBV¤Î»î¤ß
2011ǯ2·î Âè94²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ²»ÌîͳÈþ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ë²èÁü¾å¡ÊEOB MRI, ·ì´É¤±ÆCT¤ò´Þ¤à¡Ëŵ·¿ÅªHCC pattern¤ò¤È¤Ã¤¿15mmÂç¸Â¶ÉÀ­·ëÀáÀ­²á·ÁÀ®¡ÊFNH¡ËÍÍ·ëÀá¤Î°ìÎã


¢¥¤³¤Î¥Ú¡¼¥¸¤ÎTOP¤Ø

©2001-2012 KOBE ASAHI HOSPITAL. All Rights Reserved.